Yingying Zhu

Aug 12, 2024 | dx.doi.org | Jiajun Chen |Dawei Ni |Yingying Zhu |Wei Xu

Aug 12, 2024 | pubs.acs.org | Jiajun Chen |Dawei Ni |Yingying Zhu |Wei Xu

Jun 26, 2024 | mdpi.com | Biao Zhang |JING CHEN |Yingying Zhu

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jan 26, 2024 | mdpi.com | Chaoran Li |Yingying Zhu |Jinyuan Zhu |Yifan Zhao

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Oct 27, 2023 | lexology.com | Yingying Zhu

IntroductionWith the development of science and technology, the patentability of biotechnology, especially human genes, has always been in dispute. Proponents argue that human genes should be patented without restriction, and that any possible challenges and concerns can be addressed by patent standards. This article will first analyz patent systems in the United States and Europe to examine the patentability of genes, and the role of patent standards in protecting human genetic development.